Piper Sandler raises NeoGenomics target to $24 from $21
Piper Sandler raised its price target for NeoGenomics to $24 from $21.
Related stories
Jiangxi Copper falls more than 6% again intraday
M impact | EQUITY | Oct 30, 2026, 08:57 AM UTC
Court Accepts Bankruptcy Liquidation Application Against CNG Weihai
A court accepted a bankruptcy liquidation application against CNG Weihai on Oct. 29, 2026.
M impact | EQUITY | Oct 30, 2026, 08:56 AM UTC
FOKUS 3-BP Reports Record Third-Quarter Profit
M impact | EQUITY | Oct 30, 2026, 08:51 AM UTC
BP reports record $8.46 billion third-quarter profit, beats forecasts
M impact | EQUITY | Oct 30, 2026, 08:49 AM UTC
Intel Reports Third-Quarter Profit; Shares Fall on Weak Outlook
Intel reported a profit for the third quarter, while its shares fell amid weak projections.
M impact | EQUITY | Oct 30, 2026, 08:43 AM UTC
2CRSI Shares Fall 11.4% After Independent Expert Conclusions Published
2CRSI published conclusions from an independent expert appointed following a Grizzly Research report.
M impact | EQUITY | Oct 30, 2026, 08:41 AM UTC